Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia

por Karp, Judith E, Lancet, Jeffrey E
Publicado 2008

Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia

por Raponi, Mitch, Belly, Robert T, Karp, Judith E, Lancet, Jeffrey E, Atkins, David, Wang, Yixin
Publicado 2004

Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysi...

por Cortes, Jorge E., Lin, Tara L., Asubonteng, Kobby, Faderl, Stefan, Lancet, Jeffrey E., Prebet, Thomas
Publicado 2022

Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML

por Cortes, Jorge E., Lin, Tara L., Uy, Geoffrey L., Ryan, Robert J., Faderl, Stefan, Lancet, Jeffrey E.
Publicado 2021

Integrative molecular subtypes of acute myeloid leukemia

por Mo, Qianxing, Yun, Seongseok, Sallman, David A., Vincelette, Nicole D., Peng, Guang, Zhang, Ling, Lancet, Jeffrey E., Padron, Eric
Publicado 2023

Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia

por Kuenzi, Brent M., Remsing Rix, Lily L., Kinose, Fumi, Kroeger, Jodi L., Lancet, Jeffrey E., Padron, Eric, Rix, Uwe
Publicado 2019

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome

por Komrokji, Rami S., Singh, Avani M., Ali, Najla Al, Chan, Onyee, Padron, Eric, Sweet, Kendra, Kuykendall, Andrew, Lancet, Jeffrey E., Sallman, David A.
Publicado 2022

Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML

por Uy, Geoffrey L., Newell, Laura F., Lin, Tara L., Goldberg, Stuart L., Wieduwilt, Matthew J., Ryan, Robert J., Faderl, Stefan, Lancet, Jeffrey E.
Publicado 2022

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes

por Komrokji, Rami S., Aguirre, Luis E., Al Ali, Najla H., Chan, Onyee, Xie, Zhuoer, Kuykendall, Andrew, Sweet, Kendra, Lancet, Jeffrey E., Padron, Eric, Sallman, David A.
Publicado 2023

Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia

por Talati, Chetasi, Dhulipala, Varun C, Extermann, Mar tine, Ali, Najla Al, Kim, Jongphil, Komrokji, Rami, Sweet, Kendra, Kuykendall, Andrew, Sehovic, Marina, Reljic, Tea, Djulbegovic, Benjamin, Lancet, Jeffrey E.
Publicado 2020

Responses to Sars-Cov-2 Vaccines in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

por Jain, Akriti G, Dong, Ning C., Ball, Somedeb, Tan, Elaine S, Whiting, Junmin, Komrokji, Rami S., Sweet, Kendra, Chan, Onyee, Sallman, David A., Padron, Eric, Kuykendall, Andrew T., Giuliano, Anna, Lancet, Jeffrey E.
Publicado 2021

Generation of Antitumor T Cells For Adoptive Cell Therapy With Artificial Antigen Presenting Cells

por Shrestha, Bishwas, Zhang, Yongliang, Yu, Bin, Li, Gongbo, Boucher, Justin C., Beatty, Nolan J., Tsai, Ho-Chien, Wang, Xuefeng, Mishra, Asmita, Sweet, Kendra, Lancet, Jeffrey E., Kelley, Linda, Davila, Marco L.
Publicado 2020

Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin

por Wang, Chen, McGraw, Kathy L., McLemore, Amy F., Komrokji, Rami, Basiorka, Ashley A., Al Ali, Najla, Lancet, Jeffrey E., Padron, Eric, Kosmider, Olivier, Fontenay, Michaela, Fenaux, Pierre, List, Alan F., Sallman, David A.
Publicado 2021

Immunogenicity of Sars-Cov-2 mRNA 1273 Vaccine in Patients with Lymphoid Malignancies

por Dong, Ning, Jain, Akriti G, Tan, Elaine S, Ball, Somedeb, Whiting, Junmin, Gaballa, Sameh, Isenalumhe, Leidy, Bello, Celeste, Saeed, Hayder, Shah, Bijal D., Locke, Frederick L., Chavez, Julio C., Lancet, Jeffrey E., Sokol, Lubomir, Pinilla Ibarz, Javier, Giuliano, Anna
Publicado 2021

Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida

por Giuliano, Anna R., Lancet, Jeffrey E., Pilon-Thomas, Shari, Dong, Ning, Jain, Akriti G., Tan, Elaine, Ball, Somedeb, Tworoger, Shelley S., Siegel, Erin M., Whiting, Junmin, Mo, Qianxing, Cubitt, Christopher L., Dukes, Christopher W., Hensel, Jonathan A., Keenan, Robert J., Hwu, Patrick
Publicado 2022

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemi...

por Lancet, Jeffrey E., Uy, Geoffrey L., Cortes, Jorge E., Newell, Laura F., Lin, Tara L., Ritchie, Ellen K., Stuart, Robert K., Strickland, Stephen A., Hogge, Donna, Solomon, Scott R., Stone, Richard M., Bixby, Dale L., Kolitz, Jonathan E., Schiller, Gary J., Wieduwilt, Matthew J., Ryan, Daniel H., Hoering, Antje, Banerjee, Kamalika, Chiarella, Michael, Louie, Arthur C., Medeiros, Bruno C.
Publicado 2018

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes

por Sallman, David A., DeZern, Amy E., Garcia-Manero, Guillermo, Steensma, David P., Roboz, Gail J., Sekeres, Mikkael A., Cluzeau, Thomas, Sweet, Kendra L., McLemore, Amy, McGraw, Kathy L., Puskas, John, Zhang, Ling, Yao, Jiqiang, Mo, Qianxing, Nardelli, Lisa, Al Ali, Najla H., Padron, Eric, Korbel, Greg, Attar, Eyal C., Kantarjian, Hagop M., Lancet, Jeffrey E., Fenaux, Pierre, List, Alan F., Komrokji, Rami S.
Publicado 2021